Boehringer Ingelheim Saudi Arabia Recognized as ‘Top Employer for 2021’ by The Top Employers Institute

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has been recognized as a ‘Top Employer in KSA in 2021’ by the prestigious Top Employers Institute, while its international operations coveted the title of ‘Global Top Employer’ for the very first time.

While the Organization has been awarded on a country level for the past seven years, this year marked the first win for the KSA operations, as well the wider inclusion of the international Organization as a ‘Global Top Employer’, where it joins the ranks of fifteen other international organizations.  
Boehringer Ingelheim particularly impressed the certification board with its long-term strategic orientation, its modern management culture as well as strong employee communication practices. Boehringer Ingelheim’s fostering of a flexible working environment during COVID-19 helped ensure that employees were able to adapt their work in a timely manner to align with social distancing requirements and safety protocols, ensuring business continuity across its different geographies.

The inclusive corporate culture of the company was also cited as a highlight by the jury who found the Organization’s ethical, inclusive approach to corporate decisions and a clear focus on the transfer and application of company values to be highly commendable. 

The independent Top Employers Institute certifies employers worldwide who wish to offer their employees excellent working conditions and support their development. Certification is based on a multi-level program to examine human resources management with detailed final feedback. 

Waleed Mashak, General Manager and Head of Human Pharma at Boehringer Ingelheim in Saudi Arabia stated, “It is an honor to have our Boehringer Ingelheim Saudi organization recognized so highly by an institution as prestigious as the Top Employers Institute. We remain committed to our high standing as an employer within the Saudi market, ensuring that our teams are always supported in their endeavors to achieve success. Through development of our people, across learning programmes, interaction with stakeholders and the ongoing efforts to attract, develop and retain Saudi talents, we will continue to build upon the values that have earned us this award, to ensure Boehringer Ingelheim Saudi Arabia remains a leading place of work in the market.”

On this occasion, Hind Al Nawaf, Human Resources Director at Boehringer Ingelheim in Saudi Arabia said, “Employees play a central role in shaping our strategies, which also enables us to attract talent. This spans efforts across our leadership styles, people strategy and work environment, which we reflect within our talent acquisition, learning opportunities and rewards programs that benefit our teams in KSA. It is our utmost priority to create a sense of belonging with the organization and encourage employees to align with our underpinning values of ethics, integrity and sustainability, amongst others. In light of the past year, we were quick to implement supportive measures for our teams in KSA as they adapted to new ways of working which resulted in a seamless transition where all concerns and queries were addressed to ensure employees did not face unnecessary duress.”

For 135 years, Boehringer Ingelheim has been creating value through innovation for human and animal health, dedicating itself to a better world. It aims to meet this, across its markets including KSA, through excellent HR policies and people practices, covering domains such as people strategy, work environment, talent acquisition, learning, well-being, diversity, inclusion and more. The family business invests heavily in individual development opportunities through tailor-made education and training programs for all employees. This serves to enhance its existing progressive workplace culture promoting transparency, open communication and supportive forward looking campaigns.
Boehringer Ingelheim will continue on its journey to implement further employee focused initiatives, ensuring the growth, development and overarching wellbeing of its teams.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. 
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros corresponded to 18.1 per cent of net sales. 
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards humankind and the environment. 
For more information please visit  https://www.mea.boehringer-ingelheim.com/ 

For more information, please contact:

Sara Shamel
Head of External Communications – META
Boehringer Ingelheim
T: +971 553258101
sara.shamel@boehringer-ingelheim.com